ACADM

The ACADM gene encodes medium-chain acyl-Coenzyme A dehydrogenase (MCAD), an essential enzyme in the mitochondrial fatty acid beta-oxidation pathway.  

This enzyme specifically targets and breaks down medium-chain fatty acids (C4 to C12), converting them into acetyl-CoA molecules, thus providing a vital source of energy, particularly during increased metabolic demand.

Mutations in the ACADM gene can lead to medium-chain acyl-CoA dehydrogenase deficiency (MCADD), a metabolic disorder that presents challenges such as hepatic dysfunction, fasting hypoglycemia, and encephalopathy. 

These symptoms can be severe, potentially leading to infantile death if not promptly diagnosed and managed. MCADD is characterized by a disruption in the mitochondrial fatty acid β-oxidation process, crucial for energy production during fasting or heightened energy demands.

This condition emphasizes the importance of early diagnosis, typically through newborn screening and genetic testing, which can significantly improve outcomes by initiating early interventions.  Understanding the ACADM gene and its associated metabolic pathways is crucial for managing and potentially preventing the complications associated with its deficiency.

Understanding ACADM  [1., 2., 6.]

The ACADM gene encodes the medium-chain acyl-Coenzyme A dehydrogenase (MCAD) protein, which plays a critical role in the mitochondrial fatty acid beta-oxidation pathway. 

This enzyme, functioning as a homotetramer, specifically targets medium-chain fatty acids (C4 to C12). 

It catalyzes the initial step in the beta-oxidation pathway, where it facilitates the transfer of electrons from fatty acids to the electron transport chain, ultimately leading to the production of ATP, the body's primary energy currency. 

By breaking down medium-chain fatty acids into acetyl-CoA molecules, ACADM ensures a steady supply of fuel for cellular processes, especially during periods of increased energy demand.

Deficiencies in MCAD due to mutations in the ACADM gene lead to medium-chain acyl-CoA dehydrogenase deficiency (MCADD). This metabolic disorder is characterized by symptoms such as hepatic dysfunction, fasting hypoglycemia, and encephalopathy, which can be severe enough to cause infantile death. 

The gene's expression is notably high in the kidney and heart, among other tissues.

Various transcript variants and isoforms of the ACADM gene have been identified, indicating a complex regulation and function of this enzyme within different cellular contexts.  Furthermore, mutations in ACADM can significantly disrupt metabolic processes, underlining the importance of this gene in maintaining metabolic health.

ACADM in Health and Disease

ACADM in Medium-Chain Acyl-CoA Dehydrogenase Deficiency  [4., 7.]

Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is a prevalent inherited metabolic disorder often confused with sudden infant death syndrome or Reye's syndrome due to its elusive symptoms. 

This condition disrupts mitochondrial fatty acid β-oxidation, pivotal for energy production during fasting or increased energy demand. Common clinical manifestations include hypoketotic hypoglycemia, muscle weakness, lethargy, and severe neurological outcomes. 

Advances in newborn screening have enhanced prognosis by identifying both symptomatic and asymptomatic cases early, although challenges remain in detecting mild or variant forms due to heterogeneity in mutation and symptom presentation.

Genetic insights reveal that mutations such as c.985A > G commonly occur alongside novel mutations like c.600-18G > A, influencing the enzyme's efficacy. This novel splice site mutation, for example, can lead to partial missplicing, resulting in a reduction but not complete loss of enzyme function, explaining the mild clinical presentation in some cases. 

ACADM in Hepatocellular Carcinoma  [5.]

Medium-chain acyl-CoA dehydrogenase (ACADM) plays a crucial role in lipid metabolism by catalyzing the initial step of mitochondrial fatty acid beta-oxidation, essential for breaking down medium-chain fatty acids. This process is critical for reducing lipid accumulation which can otherwise fuel tumor growth, as seen in cancers like hepatocellular carcinoma (HCC). 

Research has shown that ACADM is often underexpressed in HCC, correlating with aggressive tumor characteristics and poor clinical outcomes. 

Functionally, ACADM suppression leads to increased cell motility and elevated levels of triglycerides and other lipids, underscoring its tumor-suppressive potential in liver cancer. 

The enzyme's activity is intricately regulated by the sterol regulatory element-binding protein-1 (SREBP1), which negatively impacts ACADM expression, and by caveolin-1 (CAV1), which influences fatty acid oxidation by modulating SREBP1 activity. 

Thus, targeting the ACADM pathway could be a promising strategy for managing HCC, emphasizing the importance of understanding and manipulating lipid metabolism pathways in cancer treatment.

Genetic Alterations in the ACADM Gene

The gene for the ACADM protein may contain alterations or mutations that cause increase or decrease of function of the ACADM protein.  

Testing for genetic alterations in the form of SNPs is increasingly available and can shed light on an individual’s potential for health and disease.  

What is a SNP?

A SNP, or single nucleotide polymorphism, refers to a variation at a single position in a gene along its DNA sequence.  A gene encodes a protein, so an alteration in that gene programs the production of an altered protein.  

As a type of protein with great functionality in human health, alterations in genes for enzymes may confer a difference in function of that enzyme.  The function of that enzyme may be increased or decreased, depending on the altered protein produced.  

SNPs are the most common type of genetic variation in humans and can occur throughout the genome, influencing traits, susceptibility to diseases, and response to medications.

The completion of the Human Genome Project has significantly expanded opportunities for genetic testing by providing a comprehensive map of the human genome that facilitates the identification of genetic variations associated with various health conditions, including identifying SNPs that may cause alterations in protein structure and function.  

Genetic testing for SNPs enables the identification of alterations in genes, shedding light on their implications in health and disease susceptibility.

Specific SNPs Associated with Alterations in ACADM Function

Several SNPs have been implicated with alterations in ACADM function, notably the following:  [6.]

K304E

A homozygous 985A-G transition resulting in a lysine to glutamic acid substitution; prevalent among Caucasian patients.

Y42H 

Found in compound heterozygosity with K304E in two patients with mild MCAD deficiency.

G267R

Identified in homozygosity in children from consanguineous Turkish parents.

S220L

Another mutation found in homozygosity in children from consanguineous parents, indicating a range of genetic variability.

c.449_452delCTGA

A 4-bp deletion found in 25 ACADM alleles in a Japanese cohort, causing a frameshift and premature termination.

R17H

Part of the 60% prevalent mutations in the Japanese cohort studied by Tajima et al. (2016).

G362E

Another mutation from the same cohort, highlighting diversity in mutation types.

R53C and R281S 

Additional mutations identified in the Japanese patient cohort.

199T-C (causing Y42H)

Found in neonatal screening, indicating its presence in acylcarnitine-positive samples but not necessarily associated with clinically manifest disease.

Arg256Thr

Reported in compound heterozygosity with K304E in asymptomatic siblings, suggesting a milder clinical phenotype.

Thr96Ile 

Found in U.S. newborn screening; mutation leads to exon 5 skipping and potential nonsense-mediated decay.

351A-C

A neutral polymorphic variant that inactivates an exonic splicing silencer (ESS), providing protection against other deleterious splicing mutations.

Laboratory Testing for ACADM

Genetic testing for single nucleotide polymorphisms (SNPs) typically involves obtaining a sample of DNA which can be extracted from blood, saliva, or cheek swabs. 

The sample may be taken in a lab, in the case of a blood sample.  Alternatively, a saliva or cheek swab sample may be taken from the comfort of home. 

Test Preparation

Prior to undergoing genetic testing, it's important to consult with a healthcare provider or genetic counselor to understand the purpose, potential outcomes, and implications of the test.  This consultation may involve discussing medical history, family history, and any specific concerns or questions. 

Additionally, individuals may be advised to refrain from eating, drinking, or chewing gum for a short period before providing a sample to ensure the accuracy of the test results.  Following sample collection, the DNA is processed in a laboratory where it undergoes analysis to identify specific genetic variations or SNPs. 

Once the testing is complete, individuals will typically receive their results along with interpretation and recommendations from a healthcare professional. 

It's crucial to approach genetic testing with proper understanding and consideration of its implications for one's health and well-being.

Patient-Centric Approaches

A patient-centered approach to SNP genetic testing emphasizes individualized medicine, tailoring healthcare decisions and interventions based on an individual's unique genetic makeup.

When that is combined with the individual’s health status and health history, preferences, and values, a truly individualized plan for care is possible. 

By integrating SNP testing into clinical practice, healthcare providers can offer personalized risk assessment, disease prevention strategies, and treatment plans that optimize patient outcomes and well-being. 

Genetic testing empowers a deeper understanding of genetic factors contributing to disease susceptibility, drug response variability, and overall health, empowering patients to actively participate in their care decisions. 

Furthermore, individualized medicine recognizes the importance of considering socioeconomic, cultural, and environmental factors alongside genetic information to deliver holistic and culturally sensitive care that aligns with patients' goals and preferences. 

Through collaborative decision-making and shared decision-making processes, patients and providers can make informed choices about SNP testing, treatment options, and lifestyle modifications, promoting patient autonomy, engagement, and satisfaction in their healthcare journey.

Genetic Panels and Combinations

Integrating multiple biomarkers into panels or combinations enhances the predictive power and clinical utility of pharmacogenomic testing. Biomarker panels comprising a variety of transporter proteins and enzymes including drug metabolizing enzymes offer comprehensive insights into individual drug response variability and treatment outcomes. 

Combining genetic SNP testing associated with drug transport, metabolism, and pharmacodynamics enables personalized medicine approaches tailored to individual patient characteristics and genetic profiles.

Biomarkers Related to ACADM

Carnitine Palmitoyltransferase I (CPT-I) Genetic Testing  [3.] 

Carnitine palmitoyltransferase I is an enzyme involved in the beta-oxidation of long-chain fatty acids. 

Like ACADM, CPT-I plays a crucial role in fatty acid metabolism and energy production. 

CPT1A deficiency is typically confirmed through molecular genetic testing, identifying biallelic pathogenic variants in the CPT1A gene.  Alternatively, a diagnosis can be made by measuring reduced activity of the CPT 1 enzyme in cultured skin fibroblasts, especially when genetic testing does not provide conclusive results.

During diagnosis, it's common to find enzyme activity ranging from 1%-5% of normal.

Plasma Acylcarnitines

Plasma acylcarnitines are intermediates of fatty acid metabolism and serve as biomarkers for assessing mitochondrial function and fatty acid oxidation. 

Abnormal profiles of plasma acylcarnitines, characterized by elevated levels of specific acylcarnitine species, may indicate disruptions in fatty acid oxidation pathways. 

Quantitative analysis of plasma acylcarnitines using mass spectrometry techniques provides valuable diagnostic information for metabolic disorders, including those related to ACADM deficiency.

Urinary Organic Acids

Urinary organic acids are metabolic byproducts excreted in the urine and can serve as indicators of aberrant metabolic pathways.  Abnormalities in urinary organic acid profiles, such as the presence of dicarboxylic acids or ketone bodies, may suggest deficiencies in fatty acid oxidation enzymes, including ACADM. 

Quantitative analysis of urinary organic acids via gas chromatography-mass spectrometry aids in the diagnosis and monitoring of metabolic disorders associated with impaired fatty acid metabolism.

Glucose and Insulin Levels

Glucose and insulin levels provide insights into carbohydrate metabolism and insulin sensitivity, which interact with fatty acid oxidation pathways.  

Dysregulation of glucose metabolism, such as insulin resistance or hyperglycemia, can influence fatty acid oxidation and exacerbate metabolic dysfunction. 

Monitoring glucose and insulin levels alongside biomarkers of fatty acid metabolism enhances the comprehensive assessment of metabolic health and informs therapeutic interventions for metabolic disorders.

Order Genetic Testing

Click here to compare genetic test panels and order genetic testing for health-related SNPs.